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Abstract
Background Direct patient reporting of adverse drug
events (ADEs) is relevant for the evaluation of drug safety.
To collect such data in clinical trials and postmarketing
studies, a valid questionnaire is needed that can measure all
possible ADEs experienced by patients.
Objective Our aim was to develop and test a generic
questionnaire to identify ADEs and quantify their nature
and causality as reported by patients.
Methods We created a draft list of common ADEs in lay-
terms, which were classified in body categories and map-
ped to the Medical Dictionary for Regulatory Activities
(MedDRA) terminology. Questions about the nature and
causality were derived from existing questionnaires and
causality scales. Content validity was tested through cog-
nitive debriefing, revising the questionnaire in an iterative
process. Feasibility and reliability were assessed using a
Web-based version of the questionnaire. Patients received
the questionnaire twice. Feasibility was assessed by the
reported time needed for completion and ease of use.
Reliability was calculated using Cohen’s kappa and pro-
portion of positive agreement (PPA) on: (1) any ADE at
patient level; (2) similar ADEs at MedDRA System
Organ Class level; and (3) the same ADE at ADE-specific
level.
Results In the development phase, 28 patients with type 2
diabetes or asthma/chronic obstructive pulmonary disease
(COPD) participated. Questions and answer options were
rephrased, layout was improved, and changes were made in
the classification of ADEs. The final questionnaire con-
sisted of 252 ADEs organized in 16 body categories, and
included 14 questions per reported ADE. A total of 135
patients using a median of five different drugs completed
the Web-based questionnaire twice. The median comple-
tion time was 15 min for patients not reporting any ADE,
and 30 min for patients reporting at least one ADE. Three
quarters of the patients found the questionnaire easy to use.
Test–retest reliability was acceptable at patient level
(j = 0.50, PPA 0.64) and at MedDRA System Organ
Class level (j = 0.52, PPA 0.54), but was low at ADE-
specific level (j = 0.38, PPA 0.38).
Conclusion We developed a generic patient-reported
ADE questionnaire and confirmed its content validity. The
questionnaire was feasible and reliable for reporting any
ADE and similar ADEs at MedDRA System Organ Class
level. Additional work is, however, needed to reliably
quantify specific ADEs reported by patients.
1 Introduction
Today, patients are increasingly involved in information
gathering and decision making at all levels of the health-
care system [1]. Patient self-reports of adverse drug events
(ADEs) are an important additional source of information
on the safety of drugs because they differ from healthcare
professional reports [2–7]. Healthcare professionals often
underestimate symptomatic ADEs experienced by patients
[7, 8]. The added value of patient reports is acknowledged
by the Food and Drug Administration (FDA) as well as the
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European Medicines Agency [9, 10]. The FDA advises the
use of patient-reported outcome (PRO) questionnaires for
the measurement of outcomes that are best known by patients
[9] (e.g., pain [11]). In PRO questionnaires, the patient is the
direct source of information without interpretation of the
responses by a healthcare professional [9, 12].
Patient-reported ADE questionnaires can be open-ended
or checklist based. Compared to open-ended question-
naires, checklist-based questionnaires are more sensitive in
identifying potential ADEs [13, 14]. However, these
methods may lack specificity in the detection of true ADEs
[13]. Adding questions per ADE on its nature and causality
might solve this problem. To assess unknown ADEs of
(new) drugs and comparing ADE profiles of different
drugs, a generic PRO questionnaire is needed that can
measure all possible ADEs [13, 15]. Most available
patient-reported ADE questionnaires focus on specific
ADEs, such as gastrointestinal ADEs [16] or ADEs specific
for a drug class, such as inhaled corticosteroids [17] or
chemotherapy [18]. Previously, a generic questionnaire
was developed that contained approximately 600 symp-
toms classified by body category [19]. More recently, a
questionnaire with 84 ADEs classified in 19 body catego-
ries was developed [3]. Although both questionnaires have
been piloted, no explicit validation has been reported.
Furthermore, both questionnaires lack questions supporting
causality assessment and questions about the nature of the
ADE such as those regarding seriousness, severity, fre-
quency, and time course, which are relevant attributes in
the evaluation of the ADE [20, 21].
The aim of our study was to develop and test a generic
questionnaire for identifying ADEs and assessing their
nature (e.g., frequency, severity) and causality as reported
by patients. We tested the content validity and feasibility of
the questionnaire as well as the reliability for reporting
ADEs.
2 Method
The study consisted of three parts: (1) development of a
draft ADE questionnaire, (2) content validation and revi-
sion of the questionnaire in an iterative process, and
(3) feasibility and reliability testing of the revised
questionnaire.
2.1 Questionnaire Development
The questionnaire consists of four sections with questions
about: (1) general patient characteristics; (2) drug use in the
past 4 weeks, diseases for which these drugs were used,
whether the patient had other diseases; (3) ADEs experi-
enced in the past 4 weeks using structured checklists; and
(4) for each ADE a question to describe the ADE in the
patient’s own words with additional questions about its
nature and causality. We expected that a period of 4 weeks
would be sufficient for capturing a wide range of ADEs for
which patients would be able to recall the relevant details.
In the development phase, ADEs were selected, named,
coded, and categorized into a body category, and questions
were constructed to assess the nature and causality of the
ADEs.
2.1.1 Adverse Drug Event (ADE) Selection and Naming
in Lay-Terms
We aimed to include a wide range of common symptomatic
ADEs. We identified possible ADEs from the Common
Terminology Criteria for Adverse Events version 4.0 [22],
and existing symptom and ADE checklists [3, 13, 18, 23–
29]. Patient-reported data about ADEs from the Lareb
Intensive Monitoring System of The Netherlands Pharma-
covigilance Centre Lareb [30] were used to translate ADEs
into lay-terms. We excluded ADEs based on laboratory
results (e.g., hyperkalemia) and those related to specific
devices (e.g., uncomfortable pressure of the mask). The
first selection included 252 possible ADEs with an open-
ended option for reporting ‘‘other’’ experienced ADEs.
2.1.2 Coding of ADEs
Two researchers (SdV and PD) independently coded each
lay-term ADE to a lowest level term of the Medical Dic-
tionary for Regulatory Activities (MedDRA) terminology
version 13.0, making use of codings suggested by phar-
macovigilance experts from Lareb. MedDRA is the
international medical terminology developed under the
auspices of the International Conference on Harmonization
of Technical Requirements for Registration of Pharma-
ceuticals for Human Use (ICH). Agreement between the
codings existed in 74 % of the ADEs. Dissimilarities were
resolved by discussion, and translation of the Dutch lay-
terms into English by a professional translator was used to
reach agreement on all MedDRA terms. Two ADEs,
‘‘Bone fracture or fractures’’ and ‘‘Stroke,’’ were classified
at a higher hierarchical ADE group definition because of
their nonspecific nature. One ADE (dry teeth) showed
overlap in the MedDRA terminology with another
included ADE (dry mouth), and they were therefore
combined.
2.1.3 Categorization of ADEs
To increase the efficiency of completing the questionnaire,
the ADEs were classified in body categories. By first
checking body categories in which patients experienced
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ADEs, they were directed to short checklists of specific
ADEs within that body category. These lists with specific
ADEs also include the option to report other ADEs. The
body categories in the initial questionnaire were based on
the classification used in the MedDRA and in existing
questionnaires [3, 19].
2.1.4 Assessing Nature and Causality of ADEs
Relevant known attributes of ADEs were duration, fre-
quency, severity, and seriousness of the ADE; its impact on
activities; and the patient’s benefit–risk assessment of the
drug [24, 30–32]. Existing questionnaires were screened
for questions covering these topics [26, 27, 33–35].
Questions regarding causality were included, based on
medical [36], and patient-reported considerations [37].
2.2 Content Validation
The draft questionnaire was subjected to cognitive
debriefing interviewing to eliminate ambiguity in questions
and answer options. Cognitive debriefing is a qualitative
interview method in which the patient’s understanding and
interpretation of items and answer options of the ques-
tionnaire are assessed [38, 39]. A separate classification
task was used to assess the appropriateness of the body
categories.
2.2.1 Study Population
Patients included in the study were 18 years or older;
diagnosed with type 2 diabetes, asthma, and/or chronic
obstructive pulmonary disease (COPD); using drugs for
these conditions; and able to speak, read, and write the
Dutch language. Patients with these diagnoses were
included to cover a population with a broad age range in
which many different types of drugs are commonly used,
both daily and as needed. Eligible patients were recruited
by three general practitioners and two dieticians in the
northern part of The Netherlands in 2011–2012.
2.2.2 Study Procedure
After signing informed consent, patients completed the
questionnaire during which they were observed by a
researcher (SdV) to detect any problems with completing
the questionnaire. Immediately thereafter, a semi-struc-
tured interview was conducted using a topic list based on
the ‘‘question-and-answer’’ model [38, 39]. A subset of
patients was asked to do a classification task, for which all
ADEs were randomly split into five lists. Patients were
instructed to classify each ADE of one list into a body
category. Each ADE was classified by at least four patients.
2.2.3 Analyses
The audio-recorded interviews were transcribed verbatim,
and transcripts were screened by two researchers (SdV and
PD) to identify problems in understanding the questions
and answer options. The questionnaire was adapted in an
iterative process by which changes were made addressing
detected problems until no new problems were identified
regarding understanding the questions and answer options
(Fig. 1) [38].
Regarding the classification task, we considered an
ADE classification as problematic when more than two
patients classified the ADE in body categories different
from our original classification, or when two patients were
consistent in choosing a different category. These prob-
lematic ADEs were subsequently judged by four additional
patients and a pharmacovigilance expert. Based on their
judgements, revisions were made. This revised question-
naire was then translated from Dutch to English by a
professional translator. The English version was screened
for differences with the original Dutch version through
informal back translation by the researchers, and final
changes were made. A Web-based version of the content-
valid questionnaire was then constructed using the Unipark
Enterprise Feedback Suite 8.0 version 1.1 (http://www.
unipark.de).
2.3 Feasibility and Reliability Testing
The Web-based version was used to assess the feasibility of
completing the questionnaire, its ability to measure the
ADEs in a consistent manner (test–retest reliability), and to
assess the impact of using body categories on feasibility
and ADE reporting.
2.3.1 Study Population
Included patients were aged 18 years or older, had been
dispensed an oral glucose lowering drug, had an e-mail
address, and were able to access the Internet. These
patients were recruited via pharmacists in the northern part
of The Netherlands in 2012.
2.3.2 Study Design and Procedure
In a test–retest design study, consenting patients received
an e-mail message with the URL (uniform resource loca-
tor) to open the Web-based version. A personal login code
was used to prevent multiple completions of patients [40].
After completion of the ADE part, questions were asked
regarding feasibility, including self-reported time to com-
plete the questionnaire and ease of use on a five-point
Likert scale. In addition, the total time between opening
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and closing of the digital questionnaire was logged (reg-
istered time), as well as the proportion of patients com-
pleting the questionnaires, and the number of ADEs
reported in the ‘‘other’’ category. One week after comple-
tion, patients received an e-mail for the second question-
naire for the reliability analysis.
Patients were randomly assigned to three groups using
simple randomization [41] to receive: (A) the same ques-
tionnaire twice (the ‘‘test–retest group’’); (B) a question-
naire with the body category structure at the first
measurement (T1) and without these categories at the
second measurement (T2) [the ‘‘group with body categories
at T1’’]; or (C) reversing the order used in B (the ‘‘group
with body categories at T2’’).
One reminder was sent to the patients who did not
complete the first questionnaire within a month. Patients
who did not complete the second questionnaire were send a
reminder twice. We aimed to include about 50 patients per
group, which has been reported as a reasonable number for
reliability studies [42].
2.3.3 Analyses
Differences in sex and age between responders and non-
responders were assessed using Chi-square and Mann–
Whitney U tests. Descriptive statistics were used for the
feasibility parameters, including self-reported completion
time, ease of use, proportion of patients completing the
questionnaires, and number of ADEs reported in the
‘‘other’’ category. ADEs that were reported as ‘‘other’’
were evaluated and, if possible, classified by the
researchers within the provided ADE lists. To assess the
number of chronic diseases, we classified each self-repor-
ted disease in 1 of 12 chronic diseases, excluding condi-
tions of normal ageing (e.g., loss of hearing).
We measured the agreement between ADE reporting at
T1 and T2 at three levels: any ADE at ‘‘patient level,’’
similar ADEs at primary System Organ Class ‘‘MedDRA
level,’’ and the same ADE at the lowest description ‘‘ADE
specific level.’’ Cohen’s kappa coefficient and proportion
of positive agreement were calculated as measures of
agreement. Especially at the lowest level, where specific
ADEs will be checked by few patients, the kappa statistic is
negatively affected by the skewed distribution and pro-
portion of positive agreement has been proposed as an
alternative [43]. The proportion of positive agreement was
calculated by the formula 2a/[N ? (a - d)], in which N is
the total number of observations, a is the number of pa-
tients reporting ADE at T1 and T2, and d is the number
of patients not reporting ADE at T1 and T2 [44]. Kappa
and proportion of positive agreement values of [0.5 were
considered to be acceptable [45]. We conducted additional
analyses aggregating experienced ADEs using the patients’
own description of the ADEs. Based on these descriptions,
two researchers (SdV and PD) clustered ADEs that were









independent screening of 













Fig. 1 Iterative process in
adapting the developed
questionnaire to a content-
validated questionnaire
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being one problem. Although one might expect that this
clustering is similar to the aggregation at MedDRA level,
it is possible that patients use terms from different Med-
DRA classes to describe one problem. For instance, goose
bumps, shivering, and cold limbs can be seen as one
problem by the patient but are coded in different primary
MedDRA System Organ Classes. Misclassification can
also occur when patients check similar but not the same
symptomatic ADEs at T1 and T2. Finally, we calculated
how often patients checked a symptom only as a symptom
at one time point but as a possible ADE at another time.
The effect of including body categories was tested by
comparing feasibility parameters and the number of
reported ADEs between the questionnaire with body cate-
gorization and without at baseline, using Chi-square and
Mann–Whitney U tests. Additionally, the agreement values
of the group with the body categories at T1 and the group
with the body categories at T2 were compared using the
normal curve deviate statistic (Z value) [46].
Sensitivity analyses were conducted to investigate
whether the number of days between completing the first
and second questionnaire influenced the agreement values.
All analyses were conducted using IBM SPSS Statistics
version 20 (Armonk, New York, USA). P-values of \0.05
were considered to be statistically significant.
3 Results
3.1 Questionnaire Development
The initial version of the questionnaire contained 252
ADEs categorized in 21 body categories, and 11 questions
regarding the nature and causality assessment for every
ADE identified.
3.2 Content Validation
Twenty-eight patients, 54 % of them women, participated
(Table 1). Ages ranged from 22 to 90 years, with a median
of 61 years. Almost all patients used more than one drug.
3.2.1 Content Validation, Cognitive Debriefing Interviews
Based on the cognitive debriefing interviews, the ques-
tionnaire was revised 14 times. This included a revision of
the general structure of the questionnaire, and a major
revision by asking for ADEs as well as symptoms. The
final revision was tested in five patients and no major
problems in the interpretation of questions and answer
options were detected. Problems detected in the question-
naire are presented according to the domains of the ques-
tion-and-answer model, with examples given in Table 2.
Wording of the body categories and ADEs was gener-
ally clear for the patients (Table 2: ‘‘Comprehension’’).
Several ambiguous interpretations, reading difficulties, and
vague statements were reported by patients regarding
specific question and answer options, which were subse-
quently changed. Eight patients reported that the recall
period of 4 weeks for the experienced ADEs was short
(Table 2: ‘‘Retrieval’’). Because this did not reflect the
content validation, no changes regarding the recall period
were made during the study period.
The initial questionnaire asked to indicate ‘‘experienced
ADEs.’’ However, it became clear that patients, when
confronted with a checklist of possible symptomatic ADEs,
incorrectly started to check symptoms that they actually did
not see as ADEs (Table 2: ‘‘Judgement’’). Asking to check
both experienced symptoms and ADEs solved this prob-
lem. The answer option ‘‘do not know’’ was added because
some patients were not sure whether the experienced
symptom was related to a drug they used. Almost half of
the patients either skipped the body categories to go
directly to the specific checklists (navigation) or had dif-
ficulties in deciding which body category their symptom
might be classified into. Other patients who used the body
categories found them helpful and easy to use. As a result,
we kept the body category structure as a supportive step in
Table 1 Patient characteristics of content validation
Total number of participants 28 (15 women)






Type 2 diabetes 16
Asthma/COPD 10
Type 2 diabetes and asthma/COPD 2
Multiple- versus single-drug users
Multiple drug users 26
Single drug users 2
Median number of self-reported prescription
drugs (range)
5 (1–14)
Median number of self-reported chronic diseases,
including asthma/COPD, diabetes, and
cardiovascular diseases (range)
3 (1–6)
COPD chronic obstructive pulmonary disease
a No education; elementary school; junior secondary vocational
education
b Junior general secondary education; senior secondary vocational
education
c Senior general secondary education; higher professional education;
university education
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the questionnaire, but patients no longer needed to check
body categories before going to the specific checklists.
Answer options that did not fit with the judgements of
the patients were detected and adapted, and answer options
were added (Table 2: ‘‘Response’’). The answer options of
the question ‘‘how often did you experience this side effect
during the past 4 weeks (on how many or which days)?’’
were changed multiple times. Problems remained espe-
cially for intermittently occurring ADEs, and this question
was therefore adapted into an open-ended question
(Table 3).
Two questions were added to the initial questionnaire
because they yielded additional information regarding
causality (Table 3). One question was added to cover an
additional attribute, namely actions taken (Table 3).
One patient reported difficulties with the sequence of the
questions per ADE (Table 2: ‘‘Respondent burden’’). This
was improved by clustering the topics of the questions. One
patient had some problems with the size of the letters in the
questionnaire (font size 11, Arial), but none of the other
patients reported such reading difficulties. Problems
regarding navigation in the questionnaire, especially due to
layout issues were detected and resolved. After seven
interviews, the questionnaire was split into two distinct parts,
separating the specific questions about the ADEs from the
first part of the questionnaire. Two patients mentioned that
they felt many questions per ADE were included but that this
was not a problem for them. Comments on the length and
number of answer options of a causality question led to
shortening these phrases (Table 3).
3.2.2 Classification Task
Based on the classification task, where the patients had to
assign ADEs to body categories, 51 problematic ADEs
(20 %) were detected. As a consequence, we made the
following adaptations: shifting the ADE to a more fitting
body category (5 ADEs), renaming the ADE (2 ADEs), a
combination of shifting and renaming of the ADE (2
ADEs), renaming a body category (8 ADEs), combining
body categories (16 ADEs), and creating a new body cat-
egory (6 ADEs). For 12 ADEs, no changes were made.
Table 2 Examples of issues mentioned by patients per topic during the cognitive debriefing
Domain of the question-
and-answer model
Topic in topics list Examples of issues mentioned by patients
Comprehension Text ‘‘Difficult question. I do not understand it entirely. A bit difficult question. I am reading it 7
times and still do not know what they mean.’’ (female, 58 years)
Adverse drug events ‘‘Most of this is common language, no medical terms, and otherwise it is explained.’’
(female, 44 years)
Retrieval Recall ‘‘In my opinion, the period of 4 weeks is quite short.’’ (male, 61 years)
Judgement Symptom or adverse
drug event
‘‘I thought, I experience all kind of things. But if you read further, it is about medication,
then you say, no that thing has nothing to do with it. But I experience that symptom but it
has nothing to do with medication.’’ (male, 80 years)
‘‘I find it difficult to say which are side effects. I do experience symptoms but are they
symptoms or side effects. No idea. And I think I still reported it [the symptom] because I
do not know and because perhaps you may think when it is reported by everyone, it can be
a side effect.’’ (female, 61 years)
Body categories ‘‘I think of only some things with that [body category] and then later I had to go back, no,
this fits with that one [body category].’’ (female, 71 years)
‘‘Do you have problems with your eyes? Yes. Sometimes I have a blurred vision, I cannot
tolerate sunlight very well, so in that case you check eyes. Bladder, I use that tolbutamide
from which I have to pee a lot, so the bladder. The skin, I have quite a dry skin lately.
Often, my back or my hands are itching, so then you check skin. So, you just go by this
[list].’’(female, 53 years)
Response Answer options Regarding ‘‘how often’’ ADE is experienced: ‘‘Almost every day and that for a period of
14 days.’’ (female, 58 years)
Lack of… ‘‘I would include whether the side effect is treated or whether it disappeared
spontaneously.’’ (female, 44 years)
Respondent burden Structure ‘‘It can be confusing, at one time you are asked for the drug. And the next time not. Then
again about side effects, and then again about drugs.’’ (male, 58 years)
Layout ‘‘For me it [the size of the letters] is a little bit small.’’ (male, 90 years) ‘‘At a certain point I
found it [the navigation in the questionnaire] a bit chaotic.’’ (female, 44 years)
Relevance Regarding the number of answer options: ‘‘Somewhat less. Maybe half of it can go. I think,
everything a little bit more concise.’’ (female, 53 years)
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3.2.3 Final Revision
Based on the English translation, one ADE was detected
that was considered ambiguous in the original Dutch ver-
sion. To solve this, two ADE descriptions instead of one
were introduced (‘‘blood with feces’’ and ‘‘blood in
feces’’). The comparison of the English version with the
Dutch version resulted in a few minor changes regarding
the wording in both versions. Finally, after combining the
ADEs with an overlapping MedDRA term (dry teeth/
mouth), the final questionnaire contained 252 ADEs cate-
gorized in 16 body categories with 14 questions per ADE
regarding its nature and causality (Appendix I ADE ques-
tionnaire, Appendix II Questions per reported ADE, and
Table 3).
3.3 Feasibility and Reliability
In total, 187 patients gave informed consent in response to
an invitation that was mailed to 958 patients. These 187
patients were slightly younger (65 vs 67 years, Z =
-2.653, P = \ 0.01) than patients not responding. There
was no significant difference regarding sex (39.6 vs 44.7 %
women, v2 = 1.638, P = 0.20). Of the consenting patients,
Table 3 Comparison of questions regarding nature and causality of ADEs between initial and last revision
Attribute assessed Initial questiona Question in last revision Answer options
Duration/timeline Since when have you experienced this side
effect? Try to be as specific as possible (for
example 1 March 2009 or June 2010 or 2006)




Duration/timeline – New: Has this side effect gone away by now or
improved?
–
Frequency How often did you experience this side effect
during the past 4 weeks?
How often did you experience this side effect




Severity How much did this side effect bother you in the
past 4 weeks (how bad or intense was it)?
On the days that you experienced this side effect,





How much influence did this side effect have on
your daily functioning in the past 4 weeks?
On the days that you experienced this side effect,
how much influence did it have on your daily
functioning?
No changes
Actions taken – New: What action did you take in relation to this
side effect during the past 4 weeks?
–
Seriousness Did this side effect result in serious medical







How satisfied are you with the drug/drugs
described in question IV-8 when you consider
both this particular side effect and the effect of
this drug/these drugs?
How satisfied are you with the drug (or drugs)
described in question 38 when you consider
both this particular side effect and the effect of
the drug or drugs?
No changes
Causality Which drug(s) do you think caused this side
effect?
Which drug or drugs do you think caused this side
effect?
No changes
Why do you think this side effect is caused by this
drug/these drugs (several answers possible)?
Why do you think this symptom was caused by





How sure are you that this side effect is caused by
this drug?
How sure are you that this side effect is caused by
this drug or these drugs?
No changes
Do you think there are possible other factors for
your experiencing this side effect (other than
your medication)?
Do you think there are other reasons for your
experiencing this side effect (other than your
medication)?
No changes
Have you experienced this symptom in the past in
combination with other medication?
Have you experienced this side effect in the past




– New: How long had you been using this drug or
these drugs before this side effect started
occurring?
–
a The term ‘‘side effect’’ was used in the questionnaire as a lay-term for adverse drug event
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152 started with the study by opening the questionnaire,
and 137 completed both questionnaires (73.3 %). Four
times, a patient reported an ADE in the ‘‘other’’ box, which
could all be classified to one of the listed ADEs by the
researchers. One patient reported in the comments that the
reported ADE was probably not due to a drug but due to
surgery. This ADE was excluded from further analysis.
One patient was excluded from the test–retest analysis for
reporting to have experienced the ‘‘same symptoms’’ at T2
as at T1, instead of checking the symptoms again. Another
was excluded because of this patient’s comment that sev-
eral symptoms had been wrongly checked. Further analyses
were thus based on 135 patients, 45 in each group. The
median age of this population was 65 years; on average,
they used five prescription drugs (Table 4). The median
number of days between completing the first and second
questionnaires was 8 days (SD 4).
At T1, 25.2 % (N = 34) of the 135 patients reported one
or more ADEs, and 27.4 % (N = 37) at T2. In total, 173
ADEs were reported at T1, and 146 ADEs at T2. The most
common type of ADEs were gastrointestinal disorders
(Table 5). Less than 1 % of the questions about the nature
and causality of the ADE were not completed (0.4 %
missing at T1, and 0.2 % at T2). For most ADEs (124 at T1
and 96 at T2), patients checked only one reason for sus-
pecting the ADE. The most common reason was that they
did not experience the symptom before they took the drug.
In three quarters of the cases, the patients indicated which
drug they thought caused the symptom, and in most of
these cases they were quite sure about the relationship
between the drug and the ADE (Table 5). Finally, there
were 51 cases where a symptom was reported only as a
symptom at one point but as a possible ADE at another
time (22 times as symptom at T1 but ADE at T2, and 29
times as ADE at T1 but symptom at T2).
Self-reported time for questionnaire completion was in
general lower than the registered time (Table 6). On
average, the median self-reported time was 15 min for
patients not reporting any ADE (with three patients
reporting [30 min), and 30 min for those reporting one or
more ADEs (with four patients reporting [60 min). Dif-
ferences observed in completion time between the ques-
tionnaire with and without body categorization were not
significant (Table 6). Most of the patients agreed that the
questionnaire was easy to use (74.4 % for the questionnaire
with body categories; 75.6 % for the questionnaire without
body categories), which did not significantly differ between
the two versions of the questionnaire (v2 = 0.028,
P = 0.986). Overall, this percentage was lower for patients
reporting one or more ADEs than for patients not reporting
any ADE (52.9 vs 82.2 %, v2 = 12.791, P = 0.002).
The agreement of reported ADEs regarding the test–
retest reliability was acceptable at patient level and at
MedDRA level (j[ 0.5, proportion of positive agree-
ment [0.5). At ADE specific level, the agreement was
lower (j = 0.38, proportion of positive agreement = 0.38,
Table 7). By aggregating separately checked but related
ADEs according to the patient’s own description, the 64
ADEs reported at T1 were reclassified as 34 distinct ADEs,
and the 51 ADEs at T2 as 31 distinct ADEs. There was
agreement for 16 of these ADEs and the proportion of
positive agreement was 0.49.
Agreement between the two measurements was slightly
higher for patients who completed the questionnaire
including body categories at first measurement in com-
parison to those who first completed the questionnaire
without this categorization. However, kappa values did not
significantly differ between the group with the body cate-
gories at T1 and the group with the body categories at T2
(Table 6). The two-by-two tables of the agreement analy-
ses are presented in Appendix III. The number of reported
ADEs was similar between the questionnaire with and
without body categories (Z = -0.049, P = 0.961). Sensi-
tivity analyses including only those patients who com-
pleted the second questionnaire within 10 days did not lead
to significant differences in agreement measures (Appendix
IV).
4 Discussion
We developed and tested a generic questionnaire for
patient reporting of ADEs. The questionnaire adds to the
available questionnaires in that it is both generic and
checklist-based and includes specific questions about cau-
sality, severity, duration, seriousness, and frequency of
each experienced ADE. The questionnaire is intended for
use in postmarketing studies and clinical trials.
Through cognitive debriefing interviews, significant
problems were detected in several domains of the question-
and-answer model that needed to be resolved. After initial
adaptations, some problems reoccurred, underlining the
relevance of an iterative process. The input of patients was
found to be vital for the development and content valida-
tion. It became clear that directly asking for ADEs can lead
to over-reporting because some patients accidently checked
symptoms as well as ADEs when confronted with a list of
symptomatic ADEs. While going through the lists, patients
sometimes forgot that they should only check symptoms
perceived as being ADEs. This happened even while
patients were able to distinguish ADEs from symptoms, as
has been established before [37, 47]. Some of the available
checklist-based ADE questionnaires use terms such as
symptoms, problems, and ADEs interchangeably (e.g., see
[18, 27]). We recommend clear differentiation between
symptoms that could be related to the underlying disease
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and ADEs, as is done in other checklists [23], ensuring that
respondents maintain the distinction while completing the
questionnaire. This mechanism may explain in part why
more ADEs are reported in checklists than in open-ended
questionnaires [13].
Several patients reported that a recall period of 4 weeks
was quite short, for instance, to capture ADEs that fluctuate
over time, as has been identified before [48]. On the other
hand, the period should not be too long when the aim is to
collect information on symptomatic ADEs that can be mild
in nature. The optimal recall period may depend on the
nature of the ADE [48]. Although a recall period of
4 weeks is quite common, and even shorter recall periods
have been used in ADE questionnaires [17], the reliability
of various recall periods needs to be tested in further
studies.
Reducing respondent burden is relevant for the feasi-
bility of using the questionnaire. We identified problems in
navigating the questionnaire and these were solved by
formatting the questionnaire along principles of cognitive
design [49]. Around half of the patients found the body
category structure helpful, but we detected some difficul-
ties with our initial ADE classification based on the Med-
DRA System Organ Classes. We thus adapted this to a
more patient-based classification system. The feasibility
test showed, however, that the categorization structure only
marginally decreased the time to complete the question-
naire for patients reporting at least one ADE. Only four
ADEs were reported as ‘‘other,’’ indicating that most
patients were able to identify their experienced ADE within
the provided lists. For most of the patients reporting at least
one ADE, the time needed to complete the questionnaire
was \60 min. In our opinion, this time is acceptable for a
questionnaire intended for research purposes, in which
questions about general characteristics and drug use were
included. It should, however, be noted that only a quarter
of patients reported at least one ADE. The majority of the
patients agreed that the questionnaire was easy to use, but
this number was lower for those reporting an ADE than
those reporting no ADEs. Of the patients who opened the
questionnaire, around 10 % were lost to follow-up.
Although the test–retest reliability of the patient-repor-
ted ADE questionnaire was considered acceptable at
patient level and at MedDRA level, it was below the
threshold of 0.6–0.8 recommended for reliability coeffi-
cients [50]. For ADE reporting, however, a skewed distri-
bution is observed where many patients report no ADEs on
both measurements, which decreases the kappa values used
for the reliability assessment [51, 52]. Formulas to adjust
for such effects have been proposed, for example, the
Table 4 Patient characteristics, number of adverse drug events (ADEs) reported per group (P-values for differences among the three groups)
Total Test–retest group









Number of participants 135 45 45 45
Women (%) 49 (36.3) 16 (35.6) 14 (31.1) 19 (42.2) 0.544
Median age in years (range) 65 (41–86) 64 (44–86) 67 (47–82) 63 (41–83) 0.210
Education (%) 0.796
Lowb 38 (28.1) 15 (33.3) 11 (24.4) 12 (26.7)
Middlec 50 (37.0) 13 (28.9) 17 (37.8) 20 (44.4)
Highd 40 (29.6) 14 (31.1) 15 (33.3) 11 (24.4)
Other 7 (5.2) 3 (6.7) 2 (4.4) 2 (4.4)
Median number of self-reported
prescription drugs (range)
5 (2–18) 5 (2–14) 5 (2–13) 6 (3–18) 0.095
Median number of self-reported
chronic diseases, including diabetes
and cardiovascular diseases (range)
3 (1–10) 3 (2–8) 3 (1–5) 3 (2–10) 0.367
Number of patients reporting
an ADE at T1 and T2 (%)
T1: 34 (25.2) T1: 12 (26.7) T1: 11 (24.4) T1: 11 (24.4) T1: 0.961
T2: 37 (27.4) T2: 13 (28.9) T2: 11 (24.4) T2: 13 (28.9) T2: 0.862
Number of ADEs reported (range) T1: 173 (1–19) T1: 64 (1–15) T1: 35 (1–10) T1: 74 (1–19) T1: 0.339
T2: 146 (1–11) T2: 51 (1–10) T2: 34 (1–9) T2: 61 (1–11) T2: 0.394
T1 first measurement, T2 second measurement after 1-week period
a For differences among the three groups
b No education; elementary school; junior secondary vocational education
c Junior general secondary education; senior secondary vocational education
d Senior general secondary education; higher professional education; university education
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prevalence-adjusted bias-adjusted kappa [53], but their
inappropriateness has also been demonstrated [51]. We
therefore calculated the proportions of positive agreement
as an alternative agreement measure, which showed similar
results. Future studies assessing the reliability of ADE
reporting are advised to recruit a more balanced group of
patients experiencing and not experiencing ADEs [51].
Based on a combined approach, that is, looking at kappa
values, alternative agreement measures, and additional
analysis of ADEs at patient level, we conclude that our
questionnaire was not sufficiently reliable at the ADE-
specific level. This result implies that the distinct symp-
toms reported by patients as ADEs using these checklists
should not be used blindly to quantify rates at the lowest
ADE-specific level. Part of the lack of reliability might be
solved by improving the questionnaire, but some lack of
reliability at the lowest ADE level could be inherent to
patient reporting.
One can expect that uncertainty by patients about a
symptom being an ADE may lead to inconsistent answers.
The finding that some patients checked a symptom as an
ADE on one measurement but not on the other indicates
such uncertainty. Furthermore, in around half of the cases
the patients did not mention a potential drug that they
believed was causing that specific ADE or were not very
sure about the causal relationship. On the other hand, some
of the inconsistency was caused by using a checklist that
does not require differentiation between related and dis-
parate ADEs. Patients often checked multiple related
ADEs, but not exactly the same ADEs on the two mea-
surements. When aggregated at MedDRA level or using
the patient’s own descriptions, patients were therefore
found to be more consistent. This problem could be a
consequence of direct patient reporting; that is, reporting
without involvement of a healthcare professional who can
interpret and cluster specific symptoms to a more general
ADE description. However, a more intelligent question-
naire flow or an interactive questionnaire, might solve this
problem. For instance, using an interactive questionnaire
requiring patients to cluster related symptoms that are
considered as one problem before they move to answer
more detailed questions. Such a questionnaire should
incorporate a more flexible linkage to the MedDRA
System Organ Class by not only focusing on the primary
MedDRA class. This prevents symptoms with different
primary MedDRA classes used to describe one ADE
being classified in different MedDRA classes. Notwith-
standing these possible improvements to the questionnaire,
some patients clearly checked totally different ADEs at the
two measurements. We chose a period of 1 week between
the measurements to exclude memory effects, but this
period may have been too long to exclude true changes in
the experience of ADEs in the previous 4 weeks, especially
for ADEs that might change from day to day [12].
The comparison between the questionnaire with and
without the body category structure showed no significant
Table 5 Nature and causality reported at adverse drug event (ADE)





MedDRA System Organ Class (%):
Cardiac disorders 1 (0.6) 0 (0.0)
Ear and labyrinth disorders 1 (0.6) 1 (0.7)
Eye disorders 17 (9.8) 6 (4.1)
Gastrointestinal disorders 53 (30.6) 37 (25.3)
General disorders and administration site
conditions
11 (6.4) 10 (6.8)
Infections and infestations 2 (1.2) 1 (0.7)
Injury, poisoning, and procedural complications 0 (0.0) 1 (0.7)
Investigations 4 (2.3) 9 (6.2)
Metabolism and nutrition disorders 5 (2.9) 6 (4.1)
Musculoskeletal and connective tissue disorders 4 (2.3) 5 (3.4)
Nervous system disorders 31 (17.9) 17 (11.6)
Psychiatric disorders 9 (5.2) 22 (15.1)
Renal and urinary tract disorders 2 (1.2) 2 (1.4)
Reproductive system and breast disorders 8 (4.6) 8 (5.5)
Respiratory, thoracic, and mediastinal disorders 6 (3.5) 7 (4.8)
Skin and subcutaneous tissue disorders 14 (8.1) 10 (6.8)
Vascular disorders 5 (2.9) 4 (2.7)
Number of times a reason for a relationship
among drug and ADE was reported
I did not experience this symptom before I started
taking the drug
97 87
The symptom started soon after I started taking the
drug
49 33
I experienced this symptom less often before I
started taking the drug
20 17
The symptom was less serious before I started
taking the drug
8 8
The symptom went away when I stopped taking
the drug and came back when I started taking it
again
2 2
The symptom went away when I stopped taking
the drug
5 1
The symptom started or grew worse when the drug
dosage was increased
14 9
The symptom decreased or went away when the
drug dosage was decreased
2 1
A healthcare professional (a doctor or pharmacist)
confirmed this
20 22
The symptom is described in the patient leaflet 34 22
Other 11 12
Number of times it was not known by the patient
which drug caused the ADE (%)
75 (43.4) 61 (41.8)
Patients’ certainty about the relationship
among the reported ADE and reported drug (%)a
Very sure 30 (17.3) 21 (12.1)
Quite sure 48 (27.7) 50 (28.9)
Not very sure 14 (8.1) 7 (4.0)
Very unsure 2 (1.2) 4 (2.3)
a Percentages do not sum to 100 % due to roundings or not indicating a causal drug
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differences in the number of reported ADEs or in agree-
ment measures. From this we conclude that including a
body category system did not influence the reliability of the
ADE reporting. Because the cognitive debriefing showed
that the body categories were helpful and increased the
feasibility for some patients, we still recommend the use of
such a categorization as a supportive element.
To our knowledge, this is the first study to validate a
generic patient-reported questionnaire intended for sys-
tematic data collection of ADEs. We conducted a broad
search for symptomatic ADEs, which we translated in lay-
terms and linked to MedDRA terms. The use of these
standard terms makes it possible to compare ADE data
across different studies, which is important in the evalua-
tion of drug safety [54]. We included a heterogeneous
population with respect to age and education level in the
content-validation study. Patients were selected for having
type 2 diabetes, asthma, or COPD, but many of them used
multiple drugs, and also used drugs for other diseases. We
expect that the questionnaire is suitable for adult patients
on a steady drug regimen who are able to read and write.
We cannot, however, guarantee that all ADE terms are
content valid. In addition, we tested the Dutch version of
the questionnaire. The use of the questionnaire in other
languages requires additional testing [55]. We expect that
the reliability for ADE reporting of the Web-based version
is comparable to the paper-based version. The navigation
through the questionnaire and the time needed to complete,
however, may differ between the Web-based and paper-
based versions [56]. We tested the questionnaire in an
observational, postmarketing setting. We expect that the
questionnaire is also applicable in clinical trials in which
patients are initial drug users, but this should be confirmed in
future studies. Further validation studies are needed (e.g.,
establishing the probability of a causal relationship between
the reported ADEs and the drugs using an external reference)
because content validation is an essential but only first step in
providing evidence of full validity [12, 57, 58].
Table 6 Time in minutes needed to complete the questionnaire with and without body categories for reporting no adverse drug event (ADE)
and one or more ADEs
With body categories (group with body
categories at T1 ? test–retest group, N = 90)
Without body categories (group with
body categories at T2, N = 45)
P-value
No ADE reported
Median self-reported time needed to
complete questionnaire (range; SD)
15 (3–40; 7.7) 13 (2–60; 10.7) 0.377
Median registered time needed to
complete questionnaire (range; SD)
17 (5–48; 10.1) 16 (7–82; 16.2) 0.720
One or more ADEs reported
Median self-reported time needed to
complete questionnaire (range; SD)
23 (15–240; 63.6) 40 (20–120; 29.0) 0.166
Median registered time needed to
complete questionnaire (range; SD)
54 (22–96; 24.1) 71 (32–147; 36.5) 0.115
SD standard deviation, T1 first measurement, T2 second measurement after 1-week period
Table 7 Kappa values and proportion of positive agreement for test–retest reliability and body categories at patient level, MedDRA level, and
ADE-specific level




Differences in kappa values
between group with body








Patient level (N = 45) 0.502 (0.21–0.79) 0.64 0.639 (0.37–0.91) 0.73 0.433 (0.12–0.74) 0.58 0.387
MedDRA level (N = 810) 0.521 (0.35–0.69) 0.54 0.395 (0.19–0.60) 0.42 0.264 (0.12–0.40) 0.30 0.330
ADE specific level
(N = 11,340)
0.380 (0.24–0.52) 0.38 0.259 (0.06–0.46) 0.26 0.158 (0.003–0.31) 0.16 0.301
PPA calculated by the formula 2a/[N ? (a - d)], in which N = total number of observations, a = patients reporting ADE at T1 and T2, and
d = patients not reporting ADE at T1 and T2
T1 first measurement, T2 second measurement after 1 week period, PPA proportion positive agreement, CI confidence interval
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5 Conclusions
Participants in postmarketing studies and clinical trials can
use multiple drugs that may interact and cause unexpected
ADEs. Using a generic questionnaire in which all experi-
enced ADEs can be reported by patients is therefore
important. In terms of content validity, our patient-reported
ADE questionnaire can be used for assessing the nature and
causality of symptomatic ADEs as experienced by patients
undergoing chronic drug therapy. The questionnaire is
feasible for research purposes, and reliable to identify
numbers of patients experiencing ADEs in general and at
MedDRA System Organ Class level. To quantify specific
patient-reported ADEs, improvements to the structure of
the questionnaire are required.
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